February 1, 1999
Other, more optimistic reports demonstrated the feasibility of a national PEP Hotline, PEPLine (phone # 888-448-4911) (#211). In this report, data from 5500 calls was reported, two-thirds of which were from percutaneous exposures. One third of the calls came from the exposed HCW, the other from providers. PEP was recommended in 56% of exposures, generally for 2-drug treatment. Rates of tolerance of 3-drug PEP (21.6% stopped due to side effects) and 2-drug PEP (10.4% stopped) in Italy (poster #212) were comparable to US rates. In a similar system in Canada, community exposures, community needle use, or sexual assault accounted for 25% of all calls (#214). And in San Francisco, a new program offering PEP and counseling for community exposures appeared feasible. Thus far, 328 persons had been screened, and 79% of those who began treatment finished a 4-week course, similar to completion rates in HCW's (#215).
These studies suggest that PEP is feasible in hospitals and the community and that more than three-fourths of persons can finish the regimen. The efficacy of PI-containing regimens remains to be established as the single disturbing report (210) reminds us.